MedTech Innovator

APrevent Medical Inc. is a medical device company based in Taipei, Taiwan, with an additional office in Austria. Founded in 2014, the company specializes in developing therapeutic devices aimed at enhancing the quality of life for patients affected by speech disorders. APrevent focuses on creating long-term implant systems and a speech conversion platform, along with other innovative medical equipment. Their offerings include minimally invasive ENT implants and Software-as-a-Service technologies designed to assist in the treatment of voice and communication disorders, enabling patients to improve their speech capabilities effectively.

The Shape Sensing Company specializes in advanced fiber optic 3D guidance systems that enable physicians to navigate medical devices within three-dimensional, patient-specific anatomical models. This technology is particularly beneficial in endovascular procedures, which traditionally depend on X-ray imaging for device guidance. By utilizing the company's proprietary 3D guidance workstation and guidewire, vascular surgeons and interventional radiologists can potentially reduce procedure times, lower operational costs, and enhance patient outcomes in the millions of vascular procedures performed annually in the United States. Additionally, the company collaborates with several original equipment manufacturer (OEM) partners to develop various 3D guided devices, which broadens the reach of its technology and maximizes revenue opportunities. Beyond the medical field, the company’s sensing technology has applications in industries such as aerospace, civil engineering, mining, and energy, providing significant feedback on the location and guidance of surgical tools and offering alternatives to harmful imaging methods.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Nurami Medical Ltd., established in 2014 and based in Haifa, Israel, is a clinical-stage medical device company specializing in the development of innovative solutions for soft tissue repair and regeneration following surgeries. The company's flagship product is a dural substitute patch, designed to replace the damaged dura layer protecting the brain during neurosurgeries. Nurami's technology, based on electrospinning, creates a porous scaffold that enhances tissue regeneration and incorporates a novel temperature-sensitive sealant to prevent infections and cerebrospinal fluid leaks. The company aims to improve patient outcomes and recovery by addressing unmet surgical needs.

Lattice Medical is a medical technology company based in Loos, France, founded in 2017. The company specializes in the design and manufacture of innovative prostheses for women who have undergone mastectomy due to breast cancer. Its flagship product, MATTISSE, addresses significant clinical and societal needs by enabling natural breast reconstruction. MATTISSE uses a combination of biomaterials and tissue engineering, including 3D printing, to create custom implants that regenerate autologous adipose tissue. This technology allows for a single surgical procedure, as the fully biodegradable implants dissolve after reconstruction, minimizing invasiveness and pain while reducing surgery time. Lattice Medical aims to replace traditional silicone-based implants with its advanced solutions, thereby enhancing the quality of life for women affected by breast cancer.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

Arsenal Medical, Inc. is a technology company based in Watertown, Massachusetts, specializing in the development of polymer-based foams and fibers aimed at treating vascular diseases. Founded in 2005, the company focuses on innovative approaches to local therapy for acute hemorrhage and critical clinical conditions, such as vascular injury and repair. Arsenal Medical's proprietary technologies include in-situ forming foams and AxioCore, a core-sheath nanofiber technology designed for effective cell integration and tissue regeneration. These products utilize safe, non-toxic, and biocompatible materials, allowing for targeted therapeutic delivery in complex anatomical environments. The company is advancing multiple preclinical programs and is backed by venture funding and grants from various organizations, including the Department of Defense and the Bill & Melinda Gates Foundation.

Prevencio is a company that develops multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, Prevencio's biomarkers analyze extensive clinical data sets to create innovative, multi-protein tests that are scored algorithmically. These tests assist clinicians in evaluating the effects of medications before and after administration, focusing on a composite risk assessment for heart attacks, strokes, and cardiac death. By enhancing the accuracy and effectiveness of cardiovascular diagnostics, Prevencio aims to improve patient outcomes in the realm of heart health.

REMEDI is a solution provider for radiotherapy and radiography.

SanaHeal is a company focused on developing innovative bioadhesive biomaterials, including tapes, pastes, and powders, designed to bind tissues or organs. Its bioadhesive tapes serve as an alternative to traditional sutures, promoting healing while reducing complications following surgery. This technology aims to transform the treatment of wounds and bleeding, enhancing patient outcomes. Additionally, SanaHeal's platform offers mechanical integration solutions that assist in the care of patients with multiple traumatic injuries, ensuring they receive the necessary intensive care.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

VinBrain is a healthcare technology company that specializes in artificial intelligence applications for medical diagnostics. The company has developed a platform that integrates AI to enhance patient outcomes and operational efficiency in healthcare settings. Its DrAidTM Teleradiology solution facilitates remote medical imaging, allowing hospitals to connect resources and expertise for high-quality diagnostic services accessible to patients anytime and anywhere. Additionally, VinBrain's platform can identify and differentiate various types of cancerous cells and tissues, analyze patients' medical histories for potential risk factors, and automatically generate reports based on healthcare data. By employing computer vision and generative AI, VinBrain streamlines radiologists' workflows, providing healthcare providers with valuable insights to improve diagnosis, treatment, and overall patient care.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

HealthTech Connex Inc. is a brain technology company situated in the Health and Technology District, dedicated to advancing innovations in translational neuroscience aimed at enhancing health outcomes, particularly in neurological performance. The company focuses on brain vitality and develops technology that assesses cognitive brain health across multiple conditions, including brain injuries and neurological diseases. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex enables mental health professionals to identify cognitive impairments early, thereby improving care in both clinical and community settings worldwide.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

CancerFree Biotech is a start-up focused on personalized cancer treatment through innovative technologies. The company utilizes circulating tumor cell culture to create organoid systems, which assist healthcare professionals in devising optimal treatment strategies for patients at all stages of cancer. By employing advanced bionic tumor organoid culture systems, CancerFree Biotech aims to minimize the likelihood of ineffective drug use. Their proprietary technology platform, E.V.A., combines organoid culture systems with AI image recognition to efficiently expand circulating tumor cells into cancer-derived organoids for various applications in cancer research, including cell therapy, vaccine development, and new drug discovery. This approach not only enhances the testing of anti-cancer drugs but also alleviates the burden of frequent testing for patients undergoing treatment.

Invicta Medical is a medical technology company focused on developing innovative treatments for sleep apnea and snoring. Founded in 2013 and based in California, the company has created a wearable neurostimulation device that detects and treats disturbed breathing through electrical stimulation. This device aims to overcome the limitations of traditional therapies, which are often expensive, intrusive, and associated with low patient compliance rates. By providing a smart, comfortable, and cost-effective solution, Invicta Medical seeks to enhance the effectiveness of treatment for sleep disorders and improve patient outcomes.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

Qritive is a developer of an AI-powered diagnostic platform that assists medical professionals in analyzing microscopy images and patient data. The platform leverages artificial intelligence and natural language processing to streamline the analysis process, enhancing the efficiency of cancer diagnoses. By providing modern automated tools, Qritive aims to reduce the time and costs associated with cancer diagnosis, ultimately improving healthcare outcomes for patients. The company's innovative approach addresses the challenges faced by doctors in interpreting complex medical information, facilitating quicker and more accurate diagnoses.

Acorai is developing a non-invasive heart failure monitoring platform centered on direct intracardiac pressure monitoring (ICPM). The company utilizes a patented combination of sensor technologies and machine learning to provide accurate and cost-efficient heart failure care. This innovative approach allows for non-invasive monitoring of cardiac and pulmonary pressure, which is crucial for improving outcomes in heart failure patients. By analyzing pressure dynamics through acoustic, vibratory, and waveform data, the device enables healthcare professionals to proactively adjust medications, potentially reducing re-hospitalization and mortality rates associated with heart failure. Clinically validated and designated as an FDA Breakthrough Device, Acorai's product is expected to enter the market in 2025.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

KA Imaging Inc. is a Canadian company based in Waterloo that focuses on designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. Founded in 2015, the company has developed the world's first portable dual energy subtraction X-ray detector, which enhances the sensitivity of disease identification, including conditions such as pneumonia and fractures. This innovative device, known as Reveal, has received FDA clearance and is sold globally. KA Imaging offers a range of products, including static detectors for identifying faults in infrastructure, dual-energy detectors for baggage screening, dynamic detectors for inspecting moving parts, and specialized mammography detectors. With a team of 20 full-time and 10 part-time employees, the company holds 52 global patents and 17 issued US patents, emphasizing its commitment to advancing X-ray imaging technology across various sectors.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

IFPx is a company focused on developing innovative patient monitoring technology aimed at improving the management of chronic illnesses, specifically heart failure. Its platform features advanced sensors that measure interstitial fluid pressure, allowing healthcare professionals to directly analyze fluid buildup in patients. This technology aims to enhance the monitoring and treatment of heart conditions, ultimately transforming patient care and outcomes in this critical area of healthcare.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostics aimed at identifying high-risk markers for stomach cancer. The company utilizes next-generation technology and precision immunology to create tests that exceed the capabilities of current antibody screenings, offering enhanced precision and more comprehensive disease information. By improving diagnostic accuracy, Biotome seeks to equip medical professionals with the tools necessary to provide better treatment options for patients, ultimately benefiting healthcare outcomes globally.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

Xtremedy Medical, based at NUI Galway, specializes in manufacturing innovative surgical devices. These devices use electrical signals to treat bone and deep tissue infections, including diabetic foot ulcers. By targeting both surface and underlying infections, the company's technology helps doctors enhance treatment outcomes, reducing the risk of amputations and promoting faster patient recovery.

Covellus is a medical device company focused on developing innovative catheter technologies for minimally invasive surgeries. It specializes in manufacturing vascular catheters and modular catheter systems that allow physicians to customize devices according to individual patient needs. By offering a unique platform technology, Covellus aims to enhance the effectiveness and personalization of medical treatments through its advanced product offerings.

AMI Co., Ltd, established in 2015 and headquartered in Minamata-shi, Japan, specializes in manufacturing medical equipment, notably stethoscopes. The company also offers healthcare consulting services, including hospital management and clinical research. AMI Corp's core business involves medical consulting and the development of medical devices, with a focus on telehealth solutions. It operates a telemedicine system centered around a stethoscope and has developed a video chat system for remote auscultation, enabling patients to access medical services remotely.

Renovos is an orthopedic regenerative medicine company focused on addressing the growing challenges of bone deterioration due to aging, trauma, and disease. The company develops a range of innovative products and therapeutics that aim to enhance bone healing processes, making them quicker, safer, and more cost-effective. By utilizing advanced stem cell and material technologies, Renovos seeks to meet the unmet needs of researchers and clinicians, ultimately enabling patients to recover more efficiently and alleviate pain associated with bone injuries and conditions.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

Invenio Imaging, Inc. is a privately held company founded in 2012 and based in Santa Clara, California. The company specializes in developing advanced technology for non-destructive microscopic analysis of the molecular composition of tissues and materials. Its primary product is a multi-modal coherent Raman scattering microscope, which is designed for both research and high-value medical applications. This innovative imaging system facilitates intraoperative histology by providing high-resolution images that allow researchers to examine tissue specimens from multiple surgical sites. Invenio Imaging's technology is underpinned by research from Prof. Sunney Xie at Harvard University and has received funding from the National Science Foundation and the National Institutes of Health's Small Business Innovation Research programs.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

MACH32 is a medical device company focused on developing innovative drug delivery solutions to address significant healthcare challenges. The company specializes in creating medical devices designed for the pre-hospital treatment of trauma, producing reliable and functional tools that aim to save lives in urgent situations. Their technology includes novel drug-delivery systems that enable healthcare professionals to utilize protective equipment effectively, safeguarding them from infectious aerosols, particularly highlighted during the Covid-19 pandemic. By prioritizing safety and efficacy, MACH32 addresses critical needs in emergency medical care.

Prana Thoracic, Inc. is a Houston-based medical device startup focused on addressing the challenges of early intervention in lung cancer, which remains a leading cause of cancer-related deaths in the United States. The company aims to enhance screening and diagnosis by developing advanced surgical tools that facilitate the capture and analysis of small, suspicious lung nodules. Their innovative device employs a tissue-sparing electrosurgical technique that utilizes bipolar radiofrequency energy, allowing for simultaneous cutting and sealing. This approach minimizes the risk of complications associated with traditional methods, thereby improving the prospects for early detection and treatment. By providing physicians with more effective tools, Prana Thoracic seeks to revolutionize the management of lung cancer, ensuring that patients receive timely interventions and improving overall survival rates.

InterShunt is a medical device company based in St. Louis, Missouri, founded in 2015. The company specializes in designing and developing a proprietary catheter-based system aimed at alleviating the symptoms of heart failure. Their innovative approach centers on left atrial decompression, utilizing a minimally invasive procedure that does not require any implants or energy for capturing and excising tissue from the interatrial septum. By enabling healthcare professionals to effectively reduce left atrial pressure, InterShunt seeks to provide significant relief for millions of individuals suffering from heart failure.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

PanTher Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative drug-delivery treatments for cancer. The company has created a proprietary platform that enables targeted and sustained drug administration directly at tumor sites, significantly enhancing therapeutic efficacy while minimizing the toxic side effects commonly associated with traditional chemotherapy. This approach allows oncologists to unlock the full potential of cancer drugs, particularly in challenging cases such as pancreatic cancer, where treatment options can be limited. Founded in 2014, PanTher Therapeutics aims to improve cancer care by addressing the needs of patients suffering from life-threatening malignancies.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

INBRAIN Neuroelectronics is a medical device company based in Barcelona, Spain, that specializes in developing graphene-based neural interfaces and intelligent neuromodulation systems aimed at treating brain disorders. Founded in 2019, the company offers the world's first brain-computer interface (BCI) therapeutics platform, which integrates precise BCI decoding with micrometric modulation to provide adaptive and personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. Its technology enables continuous real-time monitoring and autonomous adjustments to therapy, enhancing therapeutic outcomes while reducing side effects. INBRAIN is also engaged in strategic collaborations, including with Merck KGaA, to expand its innovative solutions into peripheral nerve and systemic disease applications, thereby advancing the field of neurotechnology and bioelectronics.

Hypervision Surgical focuses on enhancing surgical precision, safety, and efficiency through its innovative imaging technology. The company develops an advanced non-contact and non-invasive optical imaging system that employs hyperspectral imaging to analyze tissues during surgery. By splitting light into multiple spectral bands, the system provides real-time, data-driven tissue characterization, allowing clinicians to visualize and assess tissue without the need for contrast agents. This technology aims to improve surgical outcomes while minimizing risks to patients, positioning Hypervision Surgical at the forefront of AI-powered surgical assistance.

ImmersiveTouch, Inc. is a medical technology company based in Chicago, Illinois, specializing in virtual reality simulators for medical training and patient engagement. Established in 2005, the company develops applications for surgical education and pre-operative planning, utilizing its advanced Ikshana XR platform. This platform employs proprietary software and artificial intelligence to convert radiology scans into 3D simulations, allowing for detailed anatomical exploration and informed surgical decision-making. ImmersiveTouch's surgical simulators feature an immersive pod where surgeons interact with realistic 3D models, experiencing high visual acuity and realistic sensory feedback. The training modules cover various specialties, including core surgical skills, neurosurgery, orthopedic surgery, spine, and ophthalmology. By providing actionable insights, ImmersiveTouch aims to improve patient outcomes, reduce complications, and enhance the efficiency of surgical procedures.

Universal Brain is focused on creating individualized treatments for mental health by utilizing advanced neurofeedback therapy methods. The company engages in research and development of algorithms that integrate data from electroencephalograms (EEG) and magnetic resonance imaging (MRI) through deep learning techniques. This approach allows for the design and manufacturing of portable electroencephalograph headsets, enhancing the capabilities of mental health professionals in diagnosing and treating psychiatric conditions. By analyzing brain data, Universal Brain aims to provide valuable insights that improve the effectiveness of psychiatric care.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of a silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have sustained injuries due to trauma or cancer surgery. This innovative approach eliminates the risks associated with traditional autograft procedures, which are currently considered the gold standard for such repairs. By providing healthcare professionals with a new treatment option, Newrotex aims to enhance patient outcomes and reduce the morbidity associated with conventional nerve repair methods. The intellectual property for this device has been granted, underscoring its potential impact in the medical field.

Pumpinheart is a medical device company specializing in the development of an implantable left ventricular assist device (LVAD) for the treatment of heart failure with preserved ejection fraction (HFpEF). Their device, an electromedical pump, is designed to reduce left atrial pressure during diastole, improving heart function and potentially reducing hospitalizations. The pump is implanted in the left ventricle and operates in sync with the heart's natural rhythm, providing a minimally invasive treatment option for patients with HFpEF.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Knowtex offers a technology platform that utilizes artificial intelligence and voice technology to enhance the efficiency of healthcare practices. By capturing and analyzing conversations between healthcare professionals and patients, Knowtex streamlines administrative tasks and generates detailed visit notes, which include billing code suggestions and order entries. This automation allows healthcare providers to focus more on patient care while ensuring that services are billed accurately. The company aims to reduce the administrative burden on medical staff, fostering more effective communication and organization within healthcare settings. For further information, interested parties can fill out an inquiry form available on their website.

270Surgical Ltd. is a medical device company based in Netanya, Israel, founded in 2016. It specializes in the development of the SurroundScope System, an innovative laparoscopic camera designed to enhance visualization during surgery. This system features a unique 270-degree wide field of view technology, which significantly reduces blind spots and the risk of off-screen injuries, thereby improving patient outcomes. The SurroundScope also addresses common issues faced during laparoscopic procedures, such as lens fogging and visual obstructions from surgical smoke. The system has received FDA clearance and has garnered endorsements from leading experts in the field, positioning 270Surgical as a key player in advancing surgical techniques.

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

Hertility Health is a women's health company focused on reproductive and hormonal health. It aims to reshape the landscape of reproductive healthcare by offering innovative diagnostic testing that delivers insights into reproductive health, fertility decline, and menopause. Hertility enables women to understand their symptoms through community-based home testing and evidence-based medical guidance. The company provides educational resources and access to expert advice, allowing women to visualize their biological clock and reproductive biology. This approach empowers women with actionable insights and pathways to care, all from the comfort of their homes.

Nininger Medical is focused on developing a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This innovative approach aims to provide effective treatment for heart failure, particularly in preventing structural heart issues. The company has recently received a Small Business Innovation Research grant from the National Science Foundation, underscoring its commitment to advancing medical technology in the field of cardiovascular care.

CardieX Limited is a global health technology company specializing in cardiovascular health management. Founded in 1994 and headquartered in Sydney, Australia, the company designs, manufactures, and markets medical devices aimed at measuring patient risk for hypertension, cardiovascular disease, and other vascular disorders. Its product offerings include devices that utilize patented SphygmoCor technology to assess arterial stiffness and central blood pressure waveforms. Additionally, CardieX develops the Arty platform, which provides physiological and health analytics for wearable devices. The company also offers TeleHealth Services, connecting patients with health coaches through digital and mobile tools. CardieX's solutions are provided to hospitals, clinics, research institutions, and pharmaceutical companies globally. The company has strategic partnerships, including a collaboration with Blumio Inc. for developing wearable sensors and a joint development agreement with inHealth for hypertension and cardiovascular programs. CardieX was previously known as AtCor Medical Holdings Limited until its name change in June 2018.

EchoPixel, Inc. is a company that specializes in 3D medical visualization software, providing tools for medical professionals to interact with patient-specific organs and tissues in an immersive environment. Its flagship product, the True 3D Viewer, is a real-time interactive virtual reality system that enhances the ability of doctors to identify, evaluate, and dissect anatomical structures. Additionally, the True 3D Medical Education Viewer aids medical students in understanding structural 3D biology by utilizing computer tomography and magnetic resonance images. EchoPixel also offers a holographic intraoperative software that supports structural heart procedures through interactive 3D anatomical imaging. Founded in 2012 and based in Mountain View, California, the company aims to improve diagnostic and educational capabilities in the medical field through advanced imaging technology.

Travera, LLC is a biotechnology company based in Cambridge, Massachusetts, founded in 2017. It specializes in a unique measurement technology that utilizes the Suspended Microchannel Resonator (SMR), a MEMS device capable of detecting minute changes in the weight of individual cancer cells. This technology focuses on the Mass Accumulation Rate (MAR) biomarker, which indicates how cancer cells respond to various drugs within hours of exposure. By measuring these rapid changes, Travera enables oncologists to make informed decisions about which therapies to prescribe based on the actual responses of a patient’s tumor cells. This approach aims to enhance the effectiveness of cancer treatment by distinguishing between natural cell death and drug-induced cell death, thereby improving patient outcomes.

4th Dimension EMR develops electronic health record (EHR) software aimed at assisting healthcare practitioners in managing patient information and documentation. The company offers a cloud-based platform that enhances practice management by streamlining scheduling and ensuring that medical records are accessible anytime and anywhere. This software is designed to improve workflow efficiency for medical practices, allowing practitioners to focus more on patient care while effectively maintaining comprehensive records.

NXgenPort Inc focuses on enhancing cancer care through its innovative digital health technology, which includes an implanted Smart Port for remote patient monitoring between chemotherapy sessions. This system measures vital health metrics, such as cell counts and heart function, allowing for timely alerts to physicians regarding potential infections. By reducing hospitalizations and collecting critical physiological data, NXgenPort aims to improve overall patient outcomes. Additionally, the technology offers significant advantages for cancer researchers and drug delivery stakeholders by enabling them to remotely assess a participant's biological response to various interventions, thereby supporting more effective treatment strategies.

Opticyte, Inc. is a medical device company based in Seattle, WA, focused on developing innovative technology for monitoring oxygen levels in cells to prevent organ failure. Founded in 2016 as a spinoff from the University of Washington, Opticyte is creating the first Cell O2 Monitor, a noninvasive oximeter that utilizes advanced algorithms and optical spectroscopy. This device is designed to measure oxygen concentration within cells, facilitating early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By enabling clinicians to make timely treatment decisions, Opticyte aims to reduce the risk of multiple organ failure and improve patient outcomes. The company comprises a team with significant expertise in engineering, regulatory affairs, and communications, dedicated to bringing this essential medical technology to market.

SafeGuard Surgical is a medical device company focused on improving surgical outcomes and patient safety. It develops innovative, resorbable products designed to enhance colonic anastomotic healing and stability during advanced surgical procedures. These include a resorbable intraluminal stent graft and an extraluminal resorbable graft, along with anvil cap extension arms. By employing these products, SafeGuard aims to reduce surgical complications, lower healthcare costs, and minimize patient recovery time, ultimately preventing mortality and morbidity associated with surgery.

Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. Its unique intellectual property allows for the painless delivery of electroporation energy through endoscopic procedures, significantly improving the treatment of cancer. This technology enables endoscopists to perform pulse field ablation safely and efficiently, ultimately aiming to enhance patient outcomes and experiences in cancer treatment.

DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

Sentante is a medical device company focused on developing robotic teleoperated systems specifically for endovascular procedures. By utilizing this innovative technology, Sentante enables physicians to perform surgeries remotely, significantly reducing their exposure to harmful X-rays. The company has designed a manipulator that assists endovascular practitioners in conducting procedures with minimal radiation risk, promoting safer practices in the medical field. Additionally, Sentante's robotic systems facilitate minimally invasive coronary procedures, enhancing the ability of surgeons to carry out complex endovascular surgeries while also contributing to a decrease in oncological diseases among healthcare personnel.

SUTUREGARD Medical, Inc. is a medical device company based in Portland, Oregon, specializing in the development and manufacture of innovative wound closure devices. The company offers products designed to simplify surgical procedures and improve patient outcomes. Notably, the SUTUREGARD ISR device facilitates stress-relaxation in suture applications, effectively addressing issues related to skin stretch and tension in surgical wounds. Additionally, the HEMIGARD ARS is an adhesive retention suture device that enhances skin strength, allowing for linear wound closure while minimizing the risk of skin tearing. Founded in 2014, SUTUREGARD Medical aims to provide solutions that enable painless wound healing, particularly for high-tension and fragile skin wounds, thereby reducing damage compared to traditional suturing methods.

Gradient Denervation Technologies is a Paris-based company founded in 2019 that focuses on the development of an endovascular catheter-based medical device designed to treat pulmonary hypertension. This innovative technology aims to reduce pulmonary vascular resistance and enhance cardiovascular hemodynamics through a minimally invasive procedure. The device is built on prior research and intellectual property developed at Stanford University and offers a novel approach to pulmonary artery denervation, addressing heart failure and associated pulmonary hypertension. By providing a reliable and effective treatment option, the company seeks to improve patient outcomes in the healthcare industry.

Epineuron Technologies, Inc. is a medical device company based in Hamilton, Canada, focused on developing innovative treatment solutions for peripheral nerve injuries. Founded in 2016, Epineuron is pioneering bioelectronic medicine with a mission to set new standards in nerve repair and regeneration. The company is creating a range of surgical solutions, including an electroceutical device that provides electrical stimulation to enhance the natural healing processes of injured peripheral nerves. By accelerating nerve regeneration, Epineuron aims to offer patients advanced care options and aims to establish itself as a leader in the field of bioelectronic nerve therapy.

MicroGEM is a microbiology research company focused on democratizing molecular biology by transferring complex molecular biology techniques from specialized laboratories to non-laboratory environments. The company employs an innovative enzymatic method for nucleic acid extraction, which facilitates sample preparation compatible with PCR (polymerase chain reaction) analysis. This technology supports the development of portable diagnostic devices aimed at managing infectious diseases and enhancing personalized medicine applications, making advanced molecular biology accessible to a broader audience.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Ad Vital is a digital marketing tool specifically designed for medical practices, particularly in the plastic surgery and aesthetic fields. The company offers a platform that includes lead management and automation software, which helps automate repetitive tasks. By utilizing artificial intelligence-powered chatbots and automation features, Ad Vital enables medical practices to streamline their processes, enhance patient communication, and reduce the workload on staff. This allows practices to effectively attract, convert, and retain more patients while minimizing effort and resources.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Garwood Medical Devices, LLC is a Buffalo, New York-based company that specializes in developing and manufacturing medical devices focused on infection management, particularly related to prosthetic implants and wound healing. The company's flagship product, BioPrax, is a minimally invasive device designed to target and eliminate biofilm infections on prosthetic knee implants during early intervention procedures. This innovative approach allows medical practitioners to effectively treat implant infections without the need for follow-up surgeries, thereby enabling patients to retain their implants. Founded in 2014 and initially known as Enermed, LLC, the company adopted its current name in December 2015, reflecting its commitment to advancing medical technology in infection control.

Moon Surgical is a medical device company focused on enhancing laparoscopic surgery through its innovative Maestro System. This system is designed to facilitate access to minimally invasive surgical techniques while optimizing resource utilization in the operating room. By providing features such as stabilization and automatic positioning of endoscopes, along with organ retraction, the Maestro System aims to improve surgical efficiency and patient care. Moon Surgical's technology allows surgeons to maintain their existing workflows and techniques, integrating the advantages of robotic assistance without disrupting traditional practices. Through its commitment to advancing surgical technology, Moon Surgical seeks to transform the landscape of surgery today.

Bright Uro is an early-stage medical technology company focused on developing innovative diagnostic devices for urology. The company has created a glean urodynamics system that combines advanced hardware, software, and data science to deliver wireless, catheter-free urodynamics. This system aims to enhance the accuracy and comfort of urological assessments, ultimately transforming the standard of care for patients with lower urinary tract symptoms and diseases. By providing actionable insights, Bright Uro empowers clinicians to improve patient outcomes and streamline the treatment process.

Aqua Medical, Inc. is focused on developing innovative, vapor-based, endoscopic ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 and based in Santa Ana, California, the company utilizes high-temperature water vapor generated by a radiofrequency generator. This vapor is delivered endoscopically through proprietary catheters, allowing for a minimally invasive approach to treat various conditions within the gastrointestinal tract, including pancreatic cysts and esophageal issues. Aqua Medical's platform technology offers a convenient and effective alternative to traditional surgical methods, enhancing treatment options for medical practitioners and their patients.

CardiaCare is a developer of a wearable medical device aimed at the non-invasive treatment and monitoring of atrial fibrillation (AFib) in patients at home. The device employs a closed-loop approach and machine learning algorithms to deliver personalized peripheral neuromodulation therapy. This innovative technology mediates a cardiovascular antiarrhythmic response, helping users to alleviate the burden of atrial fibrillation and address precursors such as premature atrial contractions. As a result, CardiaCare’s device offers users the potential for rapid clinical and symptomatic relief.

SafeBeat Rx specializes in advanced electrocardiogram technology that enhances cardiac monitoring by allowing patients to manage their care remotely. The company's software facilitates remote patient monitoring, continuous telemetry, and event monitoring, thus eliminating the need for prolonged hospital stays. SafeBeat Rx's solutions are particularly beneficial for arrhythmia patients, as they enable safe initiation of medications and ongoing management from home. Powered by automated artificial intelligence, their technology also supports the monitoring of cardiac implantable electronic devices, making cardiac care more accessible and efficient for patients.

Liquet Medical is a medical device development company focused on improving the treatment of vascular disease through innovative localized drug delivery methods. The company's flagship product, the Versus Catheter, features a dual-tip infusion design, real-time pressure monitoring, and a flow-directed placement balloon. These advancements aim to enhance patient outcomes and promote healthcare sustainability by providing healthcare professionals with more effective tools for managing vascular conditions. Liquet Medical's commitment to developing patented technologies positions it as a significant player in the medical device sector.

Augment Health focuses on enhancing the management of bladder dysfunction, particularly for the 7 million patients affected by neurological diseases or injuries. The company is developing a noninvasive bladder monitor along with an AI algorithm that allows for home diagnostics, addressing the high rate of inconclusive results seen in clinical settings. By shifting bladder health monitoring out of the clinic, Augment Health's technology aims to prevent complications such as bladder muscle atrophy by notifying patients or caregivers when the catheter is full, thus promoting better bladder health management. This innovation targets a significant market valued at $12.3 billion, providing a practical solution to improve the quality of life for individuals facing bladder dysfunction.

SymPhysis Medical focuses on developing innovative medical technologies aimed at treating chronic diseases, with an emphasis on enhancing patient experience and quality of life. The company's flagship product, releaze, addresses malignant pleural effusion (MPE), a common complication in late-stage cancer patients that can lead to severe shortness of breath and chest pain. This therapeutic device is designed for home use, effectively draining excess fluid from the pleural space. By utilizing an active component that enhances fluid removal efficiency, releaze alleviates distressing symptoms and improves treatment accessibility for patients requiring indwelling pleural catheter (IPC) therapies.

ConKay Medical Systems is an early-stage medical device company focused on developing innovative solutions to address valvular regurgitation in patients suffering from progressive heart failure. The company's technology is centered around annular repair, which targets the primary cause of functional regurgitation while preserving the integrity of healthy leaflets. This approach aims to enhance the effectiveness of cardiovascular care, providing healthcare professionals with advanced tools to better manage this condition.

MeaCor Inc., based in Montreal, Canada, specializes in the development of innovative transcatheter devices designed to address heart disease, particularly valvular conditions. The company manufactures a catheter-based medical device aimed at repairing the mitral and tricuspid valves, utilizing an anchoring catheter system to facilitate these procedures. This technology focuses on transcatheter interventions that minimize the risks and trauma typically associated with conventional surgical methods. By doing so, MeaCor enables effective treatment for patients who are not candidates for traditional surgery, specifically targeting those suffering from mitral valve regurgitation.

Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

Anumana is a technology company that specializes in developing artificial intelligence algorithms to analyze electrocardiogram (ECG) data, facilitating early diagnosis of cardiovascular conditions. By leveraging advanced machine learning techniques, Anumana's platform enhances cardiac care, providing healthcare professionals with tools to identify potential heart issues efficiently. The company's focus extends beyond diagnostics to improve patient outcomes across the entire continuum of cardiovascular care, including perioperative and acute settings. Through its innovative approach, Anumana aims to refine screening processes, enabling clinicians to detect heart diseases earlier and intervene more effectively, ultimately contributing to improved healthcare delivery and management of cardiovascular health.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Forest Devices, Inc. is a medical device company based in Pittsburgh, Pennsylvania, with an additional office in Canada. Founded in 2014, the company focuses on developing innovative solutions for stroke detection. Its primary product, AlphaStroke, is a portable and non-invasive stroke screening device that assists medical personnel in identifying early signs of both ischemic and hemorrhagic strokes. This device is designed to be low-cost and durable, enabling pre-hospital providers to triage patients effectively and make timely decisions regarding their care. By improving the speed and accuracy of stroke detection, Forest Devices aims to reduce delays in critical treatment for patients experiencing strokes.

OncoRes Medical is an early-stage medical device company based in Perth, Western Australia, focused on developing an innovative imaging technology that enhances intraoperative surgical procedures. This technology, which employs a novel combination of optical coherence tomography, aims to improve surgical accuracy and reduce complication rates during breast cancer surgeries by providing real-time information that helps surgeons distinguish between tumor and healthy tissue. In collaboration with leading researchers from the University of Western Australia and the Harry Perkins Institute of Medical Research, as well as breast cancer surgeons within the Western Australian public health system, OncoRes Medical is advancing its patent-protected technology. The company is supported by funding from the Medical Research Commercialisation Fund, with the goal of transforming the standard of care in clinical applications that require detailed assessment of tissue microstructure.